pabeda1 Profile Banner
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 Profile
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦

@pabeda1

Followers
5K
Following
35K
Media
2K
Statuses
17K

Cardiologist, Associate Prof. of Internal Medicine, Rio de Janeiro State University. Passion for preventive Cardiology, heart failure, art and classical music

Rio de Janeiro, Brasil
Joined October 2012
Don't wanna be here? Send us removal request.
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
3 days
It's very likely that alirocumab prescription in Italy is covered by the health system (I didn't read the publication). Such a high peoportion of adherence would be unachievable in a country such as Brazil, where the PCSk9i cost comes out of the patient's pocket...
@markinho_gc
Marcos Gamboa
@markinho_gc
3 days
Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience. 1️⃣The OMERO study assesses the real-world management of elevated cholesterol in 🇮🇹. 2️⃣ Over two-thirds of alirocumab users achieved the
1
0
3
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
18 days
Thanks for posting it, @icorvilud, it was a privilege to have co-authored this position statement. As a contribution to your comment i wish to underscore that this high prevalence of obesity in 🇧🇷 is concentrated in the more socially deprived segment of our population. Sadly...
@icorvilud
Amelia Carro — Instituto Corvilud
@icorvilud
18 days
2025 GUIDELINE OBESITY MANAGEMENT AND PREVENTION OF CARDIOVASCULAR DISEASE 5⃣Brazilian Societies 2⃣0⃣Authors 2⃣1⃣pages 9⃣5⃣references 2⃣5⃣recommendations 2⃣Tables2⃣Figures A necessary approach in a country with prevalences of 68% overweight & 31% obesity https://t.co/UU6TnzmZbQ
1
1
5
@Melissa_M818
Melissa McKay
@Melissa_M818
1 day
🚨PSA Lawmakers: Please do NOT support @JakeAuch's "Parents Over Platforms." It's a @Google influenced bill masquerading as a child safety bill. Dangerous! Vote for the much stronger App Store Accountability Act. @BasedMikeLee @SenMikeLee @RepJames @RepGusBilirakis @JonHaidt
4
6
27
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
22 days
Aeee, pros amantes de futebol! 👇👇👇
@DanielKaiser__
Daniel Kaiser
@DanielKaiser__
22 days
A IRLANDA FEZ UM GOL NO ÚLTIMO LANCE DO JOGO CONTRA A HUNGRIA E VAI PRA REPESCAGEM! E EU VIVI ISOS NUM PUB EM DUBLIN. QUE MOMENTO! O FUTEBOL É FODA
0
0
1
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
28 days
Great collage! Glad to be "on board", always a pleasure to meet you, safe travel back from #AHA2025 !
@VietHeartPA
Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA
28 days
As #AHA25 comes to a close - i celebrate my colleagues @FredWuMD @JSpitz_MD @pabeda1 @DLBHATTMD @avolgman @kardiologykazi @EugeniaGianos @KnightSNPs
0
0
7
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
28 days
So glad to meet you, @iamritu ! #AHA2025
3
3
15
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
29 days
Cont'd #3 @DrDudenbostel @AnastasiaSMihai @DaichiShimbo @SABOURETCardio
0
3
7
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
29 days
Cont'd #2
1
2
3
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
29 days
#1 Exciting results from phase 3 trial of baxdrostat, the 1st in-class aldosterone synthase inhibitor, vs placebo in pts w/resistant hypertension: Study presented this afternoon by prof Bryan Williams at #AHA2025. Worth scrolling through the images, they speak by themselves!
1
3
12
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
29 days
#AHA2025 Interesting data presented today by @JohnKastelein: The CETP inhibitor #Obicetrapib promotes striking ⬇️ in the concentration of small dense LDL particles. Potentially a convenient association to statins in pts with diabetes and/or CKM syndrome? Looking fwd to #PREVAIL
0
13
35
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
30 days
#AHA2025: An interesting study that shows - in non-diabetic pts with #HFpEF - improvement by sotagliflozin in parameters related to LV pressure, quality of life and exercise tolerance. @SantosGallegoMD @AndrewJSauer @SJGreene_md @DLBHATTMD #cardiotwitter @mvaduganathan
0
5
11
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
30 days
#3 Summary and a take home message by discussant Donald Lloyd-Jones
0
1
14
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
30 days
#2
1
1
9
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
30 days
Thread #1 #AHA2025 #Enlicitide , a novel oral #PCSK9 inhibitor shows promising results: Similar efficacy for #LDLc lowering w/injectable PCSK9i, mean ⬇️ of LDL 55% vs placebo at wk 24, 67% of pts achieving <55 mg/dL and a good safety profile. @Drlipid @lipo_fan
1
15
45
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
Always a pleasure to catch up with @ProfKausikRay at #AHA2025
0
1
11
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#6 Insight by @PamelaBMorris summarized in slides 👇 My personal take: in patients with subclinical atherosclerosis and/or high CV risk, strike strong, possibly stronger than previously recommended by guidelines. #Vesalius support this idea!
1
1
8
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#5
1
1
6
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#4
1
0
1
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#3
1
0
1
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#2
1
0
1
@pabeda1
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
1 month
#AHA2025 What is the impact of evolocumab in high risk patients without a previous ASCVD even? The answer is provided by. #Vesalius 👇👇 Following the presentation of thesse exciting results bu @EBohula, we had insightful comments by @PamelaBMorris
1
3
16